10.41

3.07% 0.31

After Hours: 10.41

Y Mabs Therapeutics Inc (YMAB)

Overview News Price History Option Chain Financials Discussions Forecast

Y Mabs Therapeutics Inc stock is traded at $10.41, with a volume of 252.14K. It is up +3.07% in the last 24 hours and down -29.90% over the past month. Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

Previous Close:

$10.10

Open:

$10.09

24h Volume:

252.14K

Relative Volume:

0.98

Market Cap:

$466.25M

Revenue:

$84.82M

Net Income/Loss:

$-21.43M

P/E Ratio:

-11.70

EPS:

-0.89

Net Cash Flow:

$-27.23M

1W Performance:

-6.55%

1M Performance:

-29.90%

6M Performance:

-18.99%

1Y Performance:

+91.01%

1-Day Range:

$9.93

$10.49

1-Week Range:

$9.847

$11.38

52-Week Range:

$5.29

$20.90

Y Mabs Therapeutics Inc Stock (YMAB) Company Profile

Name

Y Mabs Therapeutics Inc

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

212-847-9841

Address

230 PARK AVENUE, NEW YORK, NY

Employee

100

Twitter

Next Earnings Date

2024-11-08

Latest SEC Filings

YMAB's Discussions on Twitter

Compare YMAB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
YMAB	10.41	466.25M	84.82M	-21.43M	-27.23M	-0.89
VRTX	450.97	116.38B	10.63B	-479.80M	-1.35B	13.33
REGN	738.00	82.09B	13.85B	4.65B	3.32B	35.06
ARGX	605.92	36.14B	1.86B	-40.29M	-1.28B	-4.16
ALNY	244.89	31.59B	2.09B	-332.26M	16.06M	-4.14
BNTX	113.13	27.25B	3.30B	-501.07M	1.03B	11.54

Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-16-24	Initiated	Cantor Fitzgerald	Overweight
Jun-28-24	Initiated	Truist	Buy
May-10-23	Upgrade	Wedbush	Neutral → Outperform
Apr-03-23	Downgrade	Guggenheim	Buy → Neutral
Jan-27-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Jan-05-23	Downgrade	Cowen	Outperform → Market Perform
Dec-02-22	Downgrade	BofA Securities	Buy → Neutral
Oct-31-22	Downgrade	JP Morgan	Neutral → Underweight
Oct-31-22	Downgrade	Wedbush	Outperform → Neutral
Jul-06-22	Resumed	Canaccord Genuity	Buy
Jun-24-22	Initiated	BMO Capital Markets	Outperform
Feb-03-22	Resumed	Guggenheim	Buy
Nov-19-21	Resumed	Morgan Stanley	Equal-Weight
Nov-16-21	Downgrade	JP Morgan	Overweight → Neutral
May-07-21	Upgrade	BofA Securities	Neutral → Buy
Apr-23-21	Resumed	Cowen	Outperform
Mar-22-21	Resumed	JP Morgan	Overweight
Jan-15-21	Downgrade	BofA Securities	Buy → Neutral
Nov-09-20	Reiterated	H.C. Wainwright	Buy
May-05-20	Initiated	Barclays	Overweight
May-01-20	Initiated	Janney	Buy
Apr-29-20	Initiated	Morgan Stanley	Equal-Weight
Dec-24-19	Initiated	JP Morgan	Overweight
Nov-20-19	Initiated	Guggenheim	Buy
Sep-04-19	Initiated	Wedbush	Outperform
Apr-01-19	Initiated	H.C. Wainwright	Buy
Oct-16-18	Initiated	BTIG Research	Buy
Oct-16-18	Initiated	BofA/Merrill	Buy

View All

Y Mabs Therapeutics Inc Stock (YMAB) Latest News

Nov 21, 2024

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World

Nov 21, 2024

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Nov 21, 2024

Nov 20, 2024

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2024 Earnings Call Transcript - MSN

Nov 20, 2024

Oppenheimer Begins Coverage on Y-mAbs Therapeutics (NASDAQ:YMAB) - Defense World

Nov 20, 2024

Y-mAbs started at outperform at Oppenheimer on pre-targeted radiotherapies - MSN

Nov 20, 2024

Nov 19, 2024

The Market Doesn't Like What It Sees From Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Revenues Yet As Shares Tumble 26% - Simply Wall St

Nov 19, 2024

Brain Cancer Treatment Market Growth Overview Future - openPR

Nov 19, 2024

Nov 18, 2024

Oppenheimer Initiates Coverage of Y-mAbs Therapeutics (YMAB) with Outperform Recommendation - MSN

Nov 18, 2024

Y-mAbs Therapeutics (NASDAQ:YMAB) Now Covered by Analysts at Oppenheimer - MarketBeat

Nov 18, 2024

Beyond The Numbers: 4 Analysts Discuss Y-mAbs Therapeutics Stock - Benzinga

Nov 18, 2024

Institutional investors in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) lost 25% last week but have reaped the benefits of longer-term growth - Yahoo Finance

Nov 18, 2024

Nov 17, 2024

HC Wainwright Reaffirms Buy Rating for Y-mAbs Therapeutics (NASDAQ:YMAB) - Defense World

Nov 17, 2024

Nov 16, 2024

Asia Deal Watch: Apollo Takes A Shine To Chinese Biotech’s Cardiometabolic Candidate - Scrip

Nov 14, 2024

Cantor Fitzgerald Issues Positive Outlook for YMAB Earnings - MarketBeat

Nov 14, 2024

Nov 13, 2024

Investors might be losing patience for Y-mAbs Therapeutics' (NASDAQ:YMAB) increasing losses, as stock sheds 13% over the past week - Simply Wall St

Nov 13, 2024

Nov 11, 2024

Leptomeningeal Metastases Clinical Trials 2024: FDA - openPR

Nov 11, 2024

Y-mAbs Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate DevelopmentsY-mAbs Therapeutics, a biopharmaceutical company focusing on innovative radioimmunotherapy and antibody-based products for cancer treatment, rec - Defense World

Nov 11, 2024

Nov 10, 2024

Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down After Earnings Miss - Defense World

Nov 10, 2024

Earnings call: Y-mAbs Therapeutics reports Q3 2024 financials - Investing.com India

Nov 10, 2024

Nov 09, 2024